Home/ News & Events
Registration for the GOSH Immunology Education Day is open!
We are pleased to announce that the registration for the GOSH Immunology Education Day is now open!
ASID 2023: Early-Bird registration and Abstract Submission are open!
We are pleased to announce that The African Society of Immunodeficiencies is now accepting submissions for its 2023 meeting in Casablanca, Morocco.
The ESID Biennial Meeting in 2026 will be held in Maastricht, The Netherlands!
We are excited to announce that the 22nd Biennial Meeting of ESID will be held in 2026 in Maastricht, The Netherlands!
In memoriam of Oksana Leontieva
It is with great sadness that we learned of the tragic and death of our colleague, Oksana Leontieva, a pediatric hematologist from Ukraine and a victim of a recent missile strike in Kyiv ( https://www.telegraph.co.uk/world-news/2022/10/11/ukraine-russia-war-oksana-leontyeva-killed-air-strikes-kyiv/).
We at ESID offer our deepest condolences to her family, friends and colleagues of the National Pediatric Ohmatdyt Hospital.
We take this somber moment to send our thoughts and prayers in the memory of all other fellow humans who needlessly perished as a result of the current war.
Call for observations - COPA syndrome
COPA syndrome is a recently defined type I interferonopathy caused by heterozygous mutations in the gene COPA, encoding coatomer protein subunit alpha that is involved in intra-cellular transport of cargo proteins1. Although the pathogenesis is not fully understood, mutations in COPA were shown to cause an accumulation of STING at the Golgi2 where it is activated and leads to constitutive type I interferon signalling i.e. the core feature of type I interferonopathies.
Call for participation: Malignancies in IEI – an ESID registry study
ESID registry Working Party is inviting the ESID registry participants to take part in the "Malignancies in IEI" study latest by August 31st 2022.
"Call for participation" IDDA2.1 score - an ESID registry prospective study
The IDDA score has already been available as optional module (tab) in the level 1 for your own use at the initial and follow up patient entries and is designed for all IEI with immune dysregulation. Now, I am inviting your active contribution to a prospective study until end of 2023 (prolongation possible), aiming to implement a powerful tool for assessment and monitoring of disease activity and phenotype patterns!
ESID COVID-19 Statement, March 2022
Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease, clinical phenotypes and biology, improving treatment and implementing vaccination trials. Data is accumulating about the impact of COVID-19 for patients with Inborn Errors of Immunity (IEI). The purpose of this statement is to summarise our state of knowledge and set out ESID’s current guidance for professionals in the IEI community in Europe. We will update this statement as evidence emerges.
Joint statement of solidarity and support
ESID is profoundly concerned about the grave repercussions of the conflict in Ukraine on PID community, healthcare and patients.
Together with IPOPI, INGID and J Project stakeholders, we have released a statement of solidarity and support to those impacted by the war in Ukraine.